


## OX2R-IN-1

<b>Cat. No.:</b>	HY-149014
<b>CAS No.:</b>	2639148-08-4
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>28</sub> ClN <sub>3</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	457.97
<b>Target:</b>	Orexin Receptor (OX Receptor)
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	OX <sub>2</sub> R-IN-1 (compound 15) is a low cytotoxicity profile OX <sub>2</sub> R-IN-1 antagonist (a potential OX <sub>2</sub> R binder) with an IC <sub>50</sub> value of 484 μM. OX <sub>2</sub> R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life <sup>[1]</sup> .																											
<b>IC<sub>50</sub> &amp; Target</b>	OX <sub>2</sub> Receptor																											
<b>In Vitro</b>	<p>OX<sub>2</sub>R-IN-1 (compound 15) has low cytotoxic with IC<sub>50</sub> values of 484 μM. OX<sub>2</sub>R-IN-1 (compound 15) is significant and dose-dependently reduce the signal of orexin A-evoked response (0.2 μM) in CHO-K1 cell line. OX<sub>2</sub>R-IN-1 (compound 15) has uncertain permeation through the BBB, since the PAMPA assay is limited by several drawbacks<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup>.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td colspan="3">CHO-K1 cell line</td> </tr> <tr> <td>Concentration:</td> <td colspan="3">100-1000 μM</td> </tr> <tr> <td>Incubation Time:</td> <td colspan="3">24h</td> </tr> <tr> <td>Result:</td> <td colspan="3">Exhibited low cytotoxic with IC<sub>50</sub> values of 484 μM</td> </tr> </table>				Cell Line:	CHO-K1 cell line			Concentration:	100-1000 μM			Incubation Time:	24h			Result:	Exhibited low cytotoxic with IC <sub>50</sub> values of 484 μM										
Cell Line:	CHO-K1 cell line																											
Concentration:	100-1000 μM																											
Incubation Time:	24h																											
Result:	Exhibited low cytotoxic with IC <sub>50</sub> values of 484 μM																											
<b>In Vivo</b>	<p>OX<sub>2</sub>R-IN-1 (compound 15) has a short half-life and poor bioavailability. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td colspan="3">Albino male Wistar rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td colspan="3">75 mg/kg</td> </tr> <tr> <td>Administration:</td> <td colspan="3">OX<sub>2</sub>R-IN-1 (75 mg/kg; intraperitoneal injection) blood samples are collected at 0, 5, 10, 20, 30, 40, 60, 90, 120 and 240 min with a short half-life and poor bioavailability</td> </tr> <tr> <td>Result:</td> <td colspan="3">.....</td> </tr> </table> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <thead> <tr> <th style="width: 25%;">Parameter</th> <th style="width: 25%;">Units</th> <th style="width: 25%;">Plasma</th> <th style="width: 25%;">Brain tissue</th> </tr> </thead> <tbody> <tr> <td> </td> <td> </td> <td> </td> <td> </td> </tr> </tbody> </table>				Animal Model:	Albino male Wistar rats <sup>[1]</sup>			Dosage:	75 mg/kg			Administration:	OX <sub>2</sub> R-IN-1 (75 mg/kg; intraperitoneal injection) blood samples are collected at 0, 5, 10, 20, 30, 40, 60, 90, 120 and 240 min with a short half-life and poor bioavailability			Result:	.....			Parameter	Units	Plasma	Brain tissue				
Animal Model:	Albino male Wistar rats <sup>[1]</sup>																											
Dosage:	75 mg/kg																											
Administration:	OX <sub>2</sub> R-IN-1 (75 mg/kg; intraperitoneal injection) blood samples are collected at 0, 5, 10, 20, 30, 40, 60, 90, 120 and 240 min with a short half-life and poor bioavailability																											
Result:	.....																											
Parameter	Units	Plasma	Brain tissue																									

$t_{1/2,\beta}$ (h)	$t_{1/2}$	min	9.63	14.85
$t_{\max}$	min	5	40	
$C_{\max}$	$\mu\text{mol/L}$	29.40	0.199	
AUC	$\mu\text{mol/L}\cdot\text{min}$	1362.68	18.51	
MRT	min	39.94	68.93	

## REFERENCES

[1]. Eva Mezeiova, et al. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia, *Bioorg Chem.* 2020 Oct;103:104179.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA